NCT02452008View on ClinicalTrials.gov

Study of TGF-β Receptor Inhibitor Galunisertib (LY2157299) and Enzalutamide in Metastatic Castration-resistant Prostate Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

May 3, 2016

Primary Completion Date

December 31, 2025

Study Completion Date

May 31, 2026

Conditions
Prostate Cancer
Interventions
DRUG

Enzalutamide

160mg of enzalutamide is administered orally once a day on days 1-28 of each cycle.

DRUG

LY2157299

150 mg of LY2157299 is administered orally twice a day on days 1-14 of each cycle.

Trial Locations (4)

20016

Sibley Memorial Hospital, Washington D.C.

21205

Johns Hopkins University, Baltimore

60611

Northwestern University, Chicago

60637

University of Chicago, Chicago

All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

collaborator

National Capital Foundation

UNKNOWN

lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER